Therefore, further investigations are needed to explore whether they can be considered for managing hypertension in patients with or without type 2 diabetes. Below is a discussion of published research articles that compare the analysis of different authors, which can give us greater insights into the efficacy of SGLT2 inhibitors in cardiovascular outcomes. The gene discussed is SLC5A2; the disease is Hypertension.